Oppenheimer & Co’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.1M Sell
28,773
-1,046
-4% -$568K 0.17% 123
2025
Q4
$17.3M Sell
29,819
-540
-2% -$305K 0.25% 82
2025
Q3
$14.7M Sell
30,359
-1,097
-3% -$511K 0.18% 114
2025
Q2
$12.8M Buy
31,456
+1,184
+4% +$495K 0.17% 129
2025
Q1
$15.1M Buy
30,272
+814
+3% +$441K 0.23% 83
2024
Q4
$15.3M Sell
29,458
-807
-3% -$444K 0.23% 82
2024
Q3
$18.7M Sell
30,265
-1,168
-4% -$691K 0.29% 69
2024
Q2
$17.4M Buy
31,433
+144
+0.5% +$82.5K 0.28% 72
2024
Q1
$18.2M Buy
31,289
+662
+2% +$371K 0.3% 64
2023
Q4
$16.3M Sell
30,627
-1,090
-3% -$528K 0.3% 64
2023
Q3
$16.1M Sell
31,717
-975
-3% -$520K 0.33% 56
2023
Q2
$17.1M Sell
32,692
-95
-0.3% -$51.3K 0.34% 51
2023
Q1
$18.9M Sell
32,787
-3,942
-11% -$2.22M 0.4% 43
2022
Q4
$20.2M Buy
36,729
+236
+0.6% +$125K 0.46% 34
2022
Q3
$18.5M Sell
36,493
-6,442
-15% -$3.61M 0.43% 36
2022
Q2
$23.3M Buy
42,935
+4,162
+11% +$2.29M 0.5% 30
2022
Q1
$22.9M Sell
38,773
-1,251
-3% -$719K 0.41% 41
2021
Q4
$26.7M Buy
40,024
+498
+1% +$311K 0.47% 31
2021
Q3
$22.6M Sell
39,526
-4,663
-11% -$2.56M 0.42% 38
2021
Q2
$22.3M Buy
44,189
+1,487
+3% +$702K 0.4% 41
2021
Q1
$19.5M Sell
42,702
-13,481
-24% -$6.43M 0.39% 49
2020
Q4
$26.2M Sell
56,183
-5,980
-10% -$2.8M 0.55% 26
2020
Q3
$27.4M Sell
62,163
-15,672
-20% -$6.47M 0.69% 21
2020
Q2
$28.2M Sell
77,835
-1,856
-2% -$622K 0.73% 20
2020
Q1
$22.6M Sell
79,691
-2,439
-3% -$769K 0.69% 25
2019
Q4
$26.7M Sell
82,130
-3,551
-4% -$1.08M 0.66% 24
2019
Q3
$25M Buy
85,681
+1,177
+1% +$337K 0.68% 23
2019
Q2
$24.8M Sell
84,504
-2,419
-3% -$666K 0.67% 24
2019
Q1
$23.8M Sell
86,923
-402
-0.5% -$100K 0.64% 29
2018
Q4
$19.5M Sell
87,325
-4,901
-5% -$1.15M 0.61% 32
2018
Q3
$22.5M Sell
92,226
-1,955
-2% -$450K 0.57% 35
2018
Q2
$19.5M Sell
94,181
-282
-0.3% -$59.9K 0.53% 38
2018
Q1
$19.5M Buy
94,463
+11,255
+14% +$2.36M 0.5% 42
2017
Q4
$15.8M Sell
83,208
-527
-0.6% -$101K 0.41% 49
2017
Q3
$15.8M Sell
83,735
-748
-0.9% -$135K 0.42% 51
2017
Q2
$14.7M Buy
84,483
+9,290
+12% +$1.56M 0.41% 50
2017
Q1
$11.5M Sell
75,193
-15,857
-17% -$2.42M 0.33% 68
2016
Q4
$12.8M Sell
91,050
-392
-0.4% -$57.8K 0.37% 62
2016
Q3
$14.5M Sell
91,442
-1,548
-2% -$239K 0.42% 55
2016
Q2
$13.7M Sell
92,990
-3,117
-3% -$460K 0.41% 55
2016
Q1
$13.6M Sell
96,107
-2,452
-2% -$329K 0.41% 54
2015
Q4
$14M Buy
98,559
+84
+0.1% +$11.2K 0.42% 49
2015
Q3
$12M Buy
98,475
+33,879
+52% +$4.41M 0.37% 56
2015
Q2
$8.38M Sell
64,596
-34,404
-35% -$4.49M 0.23% 97
2015
Q1
$13.3M Buy
99,000
+33,755
+52% +$4.35M 0.36% 58
2014
Q4
$8.17M Sell
65,245
-3,439
-5% -$418K 0.23% 103
2014
Q3
$8.36M Sell
68,684
-2,433
-3% -$296K 0.25% 95
2014
Q2
$8.39M Sell
71,117
-357
-0.5% -$42K 0.25% 92
2014
Q1
$8.59M Buy
71,474
+4,306
+6% +$512K 0.26% 89
2013
Q4
$7.48M Buy
67,168
+2,215
+3% +$220K 0.24% 102
2013
Q3
$5.99M Buy
64,953
+179
+0.3% +$16.2K 0.21% 125
2013
Q2
$5.48M Buy
+64,774
New +$5.39M 0.21% 120

Other funds holding TMO

Oppenheimer & Co's TMO Position: Q1 2026 in Review

Oppenheimer & Co reduced its Thermo Fisher Scientific (TMO) stake by 3.5% in Q1 2026, selling an estimated $568K and leaving 28,773 shares worth $14.1M. The position accounts for 0.17% of the portfolio, ranked #123.

Oppenheimer & Co first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $28.2M in Q2 2020. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Oppenheimer & Co held 28,773 shares of Thermo Fisher Scientific worth $14.1M as of Q1 2026.
  • Oppenheimer & Co sold 1,046 Thermo Fisher Scientific shares in Q1 2026, an estimated $568K.
  • Thermo Fisher Scientific made up 0.17% of Oppenheimer & Co's portfolio in Q1 2026, its #123 holding.
  • Oppenheimer & Co first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Thermo Fisher Scientific position peaked at $28.2M in Q2 2020.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.